# Regadenoson and Adenosine

Study · id `cardio:ct-nct01809743` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01809743](<https://clinicaltrials.gov/study/NCT01809743>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01809743

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT01809743. Randomized; no masking; primary purpose diagnostic. Start 2013-01 (registry gives no type); primary completion 2013-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT01809743, source copy `cardio:ctgov-nct01809743-2013-11-13`, retrieved 2026-10-26)
- Start date: 2013-01 (registry gives no type) (ClinicalTrials.gov record NCT01809743, source copy `cardio:ctgov-nct01809743-2013-11-13`, retrieved 2026-10-26)
- Primary completion: 2013-10 (actual) (ClinicalTrials.gov record NCT01809743, source copy `cardio:ctgov-nct01809743-2013-11-13`, retrieved 2026-10-26)
- Completion: 2013-10 (actual) (ClinicalTrials.gov record NCT01809743, source copy `cardio:ctgov-nct01809743-2013-11-13`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT01809743, source copy `cardio:ctgov-nct01809743-2013-11-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01809743-2013-11-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Regadenoson and Adenosine
- Condition: Coronary Artery Disease
- Intervention (Drug): Regadenoson central -central
- Intervention (Drug): Regadenoson peripheral - peripheral
- Intervention (Drug): Regadenoson central - peripheral
- Intervention (Drug): Regadenoson peripheral - central
- Intervention (Drug): Adenosine
- Lead sponsor: Lokien van Nunen
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Single bolus intravenous regadenoson injection versus central venous infusion of adenosine for maximum coronary hyperaemia in fractional flow reserve measurement (`cardio:pubmed-25136887`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ddfe46d6c6835c3b6c03b049c9c8e1266886d3965548873f7864bdab37f65ea9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
